Type II lipoteichoic acid and preparation method thereof
Through the pre-activated O-glycosyltrichloroacetimide ester donor glycosylation method and phosphate coupling technology, the difficulties in synthesis of type II lipid phosphoacid were solved, and its efficient preparation was achieved, supporting research in the pharmaceutical field. and application.
Patent Information
- Application Number
- CN202310591431.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-23
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-05-23
AI Technical Summary
The lack of a synthesis method of type II lipid phosphoside acid in the prior art has led to its structural complexity and the difficulty in constructing five different types of 1,2-cis glycosidic bonds, which hinders its efficient, extensive preparation and medical application.
The pre-activated O-glycosyltrichloroacetimide ester donor glycosylation method was used to construct α-configured glycosidic bonds, and a lipid phospho-millic acid skeleton was prepared by phosphate coupling, realizing the type II lipid phospho-millic acid efficient synthesis.
It provides a simple, efficient and safe preparation method, suitable for large-scale production, and the obtained type II lipid phospho-metallic acid can be used in pharmaceutical research and application, with good practical application prospects.
Smart Images

Figure CN119019478A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedicine and chemical synthesis, and specifically relates to type II lipoteichoic acid and a preparation method thereof. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] As one of the basic substances of life, carbohydrates play an important role in life activities. In view of the research value of biological activity and drug application value of carbohydrates, it is of great significance to synthesize carbohydrates with uniform and clear structure.
[0004] Lipoteichoic acid (LTA) is an important component of the cell wall of Gram-positive bacteria. Its main skeleton structure is composed of hydrophilic glycerol (a small part is ribitol) phosphodiester bonds. The hydroxyl groups at the non-connected sites on the skeleton carry different numbers and types of substituents (such as D-alanine or various sugars); the end of the skeleton is connected to a lipophilic glycolipid structure and anchored to the cell membrane through a long fatty chain. As an important pathogen associated molecular pattern (PAMPs) on the surface of bacteria, lipoteichoic acid can bind to specific pattern recognition receptors (PRPs) on immune cells to activate the innate immune system to resist bacterial invasion. The efficient and large-scale preparation of lipoteichoic acid molecules will help promote in-depth research on its immunostimulatory effects and promote its medical use.
[0005] Due to the complex structure of lipoteichoic acid, its synthesis is still challenging. At present, the synthesis methods of type I, type IV and type V lipoteichoic acid have been established, but the synthesis of type II lipoteichoic acid has not been reported. The structure of type II lipoteichoic acid contains sugar chains, fat particles, sugar alcohols and phosphate backbones, and there are five different types of 1,2-cis glycosidic bonds, which is the difficulty in the synthesis of this type of molecule. Summary of the invention
[0006] In view of the deficiencies in the prior art, the present invention provides a type II lipoteichoic acid and a preparation method thereof. The present invention has a simple and efficient synthesis route, is simple and safe to operate, has strong practicability, and is easy to mass produce.
[0007] Specifically, the technical solution of the present invention is as follows:
[0008] In the first aspect of the present invention, a compound is provided, which is selected from the compounds shown in the following formula I:
[0009]
[0010] Wherein, X is independently selected from: H or fatty acyl;
[0011] The fatty acyl group may be a saturated fatty acyl group or an unsaturated fatty acyl group. In a specific embodiment of the present invention, the fatty acyl group is -COC 13 H 27
[0012] The compound also includes pharmaceutically acceptable salts or esters or solvates, tautomers, meso- and racemates, racemates, stereoisomers or metabolites thereof.
[0013] The second aspect of the present invention provides a method for preparing the above-mentioned compound, wherein the synthetic route of the compound represented by formula I comprises:
[0014]
[0015] The third aspect of the present invention provides a composition, which at least comprises the above compound.
[0016] Beneficial effects of one or more of the above technical solutions:
[0017] The above technical solution provides a type II lipoteichoic acid and a preparation method thereof. Specifically, the above technical solution adopts a glycosylation method based on a pre-activated O-glycosyl trichloroacetimidate donor to sequentially construct different types of α-configuration glycosidic bonds in the molecule; and prepares the lipoteichoic acid backbone unit through phosphate coupling. The preparation method has the advantages of high conversion rate, low cost, and large-scale preparation. The obtained type II lipoteichoic acid compound can be used as an important component of the cell wall of Lactococcus gasseri and its structural analogues, and thus used in research in the fields of medicine and so on, and therefore has good practical application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present application. The illustrative embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.
[0019] Figure 1 : NMR spectrum of compound 1-1;
[0020] Figure 2 : NMR spectrum of compound 1-2;
[0021] Figure 3: NMR spectrum of compound 3-1;
[0022] Figure 4 : NMR spectrum of compound 3-2;
[0023] Figure 5 : NMR spectrum of compound 4-1;
[0024] Figure 6 : NMR spectrum of compound 5-1;
[0025] Figure 7 : NMR spectrum of compound 5-2;
[0026] Figure 8 : NMR spectrum of compound 5-3;
[0027] Fig. 9 : NMR spectrum of compound 5-4. DETAILED DESCRIPTION
[0028] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.
[0029] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, it will be described in detail below in conjunction with specific embodiments.
[0030] In a typical embodiment of the present invention, a compound is provided, which is selected from the compounds shown in the following formula I:
[0031]
[0032] Wherein, X is independently selected from: H or fatty acyl; n is selected from 1-50, and further n is selected from 16-40;
[0033] The fatty acyl group may be a saturated fatty acyl group or an unsaturated fatty acyl group. In a specific embodiment of the present invention, the fatty acyl group is -COC 13 H 27
[0034] The compound also includes pharmaceutically acceptable salts or esters or solvates, tautomers, meso- and racemates, racemates, stereoisomers or metabolites thereof.
[0035] In another specific embodiment of the present invention, a method for preparing the above-mentioned compound is provided. In the preparation method, the synthetic route of the compound represented by formula I comprises:
[0036]
[0037] Specifically, the preparation method comprises:
[0038] S1. Compound 1 and N,N-diisopropylammonium tetrazolium salt are reacted at room temperature for a period of time, and then 2-cyanoethyl N,N,N,N-tetraisopropylphosphorodiamidite is added to continue the reaction until completion, and the semi-solid product 2 is obtained by filtration and concentration, and is directly used in the next step of synthesis without purification;
[0039] S2. Compound 2 and compound 3 are reacted under tetrazole conditions until the raw materials completely disappear, the reaction system is placed in an ice-water bath, tert-butyl peroxide is added and stirring is continued until the reaction is completed, and compound 4 is obtained by purification.
[0040] S3. Removing the protecting group from compound 4 gives compound 5.
[0041] Wherein, the compound 1 may be compound 1-1 or compound 1-2; the compound 3 may be compound 3-1 or compound 3-2;
[0042]
[0043] The compound 4 can be compound 4-1, compound 4-2, compound 4-3 or compound 4-4, and the compound 5 can be compound 5-1, compound 5-2, compound 5-3 or compound 5-4.
[0044]
[0045] It should be noted that in the above compound structural formulas, Bn represents benzyl.
[0046] Furthermore, the compound 1 is prepared by a glycosylation method based on a pre-activated O-glycosyl trichloroacetimidate donor.
[0047] When the compound 1 is compound 1-1, its synthesis route is as follows:
[0048]
[0049] Specifically, the method comprises the following steps: (1) compound 6 and compound 7 are glycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 8; (2) the compound 8 is deprotected from allyl group to obtain compound 9-1, which is then glycosylated with compound 10 by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 11-1; (3) the compound 11-1 is deprotected from TBDPS protecting group to obtain compound 12-1, which is then glycosylated with compound 7 by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 13-1; (4) the compound 13-1 is deprotected from Bz protecting group to obtain compound 1-1.
[0050] Further, when the compound 1 is compound 1-2, its synthesis route is as follows:
[0051]
[0052] Specifically, the method comprises the following steps: (1) compound 6 and compound 7 are glycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 8; (2) compound 8 is deglycosylated by removing the Bz protecting group to obtain compound 9-2, which is then deglycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 11-2; (3) compound 11-2 is deglycosylated by removing the TBDPS protecting group to obtain compound 12-2, which is then deglycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 13-2; and (4) compound 13-2 is deglycosylated by removing the allyl group to obtain compound 1-2.
[0053] Furthermore, the compound 3 is prepared by a glycosylation method based on a pre-activated O-glycosyl trichloroacetimidate donor.
[0054] When the compound 3 is compound 3-1, its synthesis route is as follows:
[0055]
[0056] Specifically, the method comprises the following steps: (1) compound 14 and compound 15 are glycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 16; (2) compound 16 is deprotected and myristoylated to obtain compound 17, which is then glycosylated with compound 19 by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 20; (3) compound 20 is deprotected by a Lev protective group and myristoylated to obtain compound 21; and (4) compound 21 is deprotected by a TBDPS protective group to obtain compound 3-1.
[0057] When the compound 3 is compound 3-2, its synthesis route is as follows:
[0058]
[0059] Specifically, the method comprises the following steps: (1) compound 14 and compound 22 are glycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 23; (2) compound 23 is deprotected and myristoylated to obtain compound 24, which is then glycosylated with compound 19 by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 25; (3) compound 25 is deprotected by removing the TBDPS protecting group to obtain compound 3-2.
[0060] In another specific embodiment of the present invention, a composition is provided, which comprises at least the above compound.
[0061] The present invention is further explained by the following examples, but they are not intended to limit the present invention. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. Wherein, Bn is benzyl, All is allyl, Bz is benzoyl, TBDPS is tert-butyldiphenylsilyl, Lev is levulinyl, and PMB is p-methoxybenzyl.
[0062] Example
[0063] 1. Preparation of compound 1-1:
[0064]
[0065] Add to the reaction flask Molecular sieves, vacuum-baked the bottle, cooled to room temperature and then purged with argon, added glycosyl donor 7 (14.0 g, 20.0 mmol), dry DCM (245 mL) and DMF (23.7 mL, 307 mmol), and stirred at room temperature for 20 minutes. The reaction mixture was then cooled to -78 °C, TfOH (1.8 mL, 20.0 mmol) was added to the reaction, and then TLC analysis showed that the glycosyl donor had completely disappeared and a new spot was generated. TBAI (37.7 g, 102 mmol) was then added, and TLC analysis showed that the second step of activation was completed. The reaction system was placed in an ice-water bath, and glycosyl acceptor 6 (3.86 g, 16.4 mmol) was added. The temperature was gradually raised to room temperature and reacted at room temperature for 48 hours. TLC analysis showed that the reaction was completed and triethylamine was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with NaHCO3 (aq.), Na2S2O3 (aq.) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give 8 (10.0 g, 80%) as a colorless oil.1H NMR(400MHz,CDCl3)δ=8.03(d,J=7.7Hz,2H,ArH),7.51(t,J=7.4Hz,1H,ArH),7.42–7.14(m,22H,ArH),5.86(ddt,J=16.3,10.8,5.5Hz,1H,CH2CH=CH2),5.25(dd,J=17.2,1.8Hz,1H,CH2CH=CH2),5.20(d,J=3.7Hz,1H,1-H),5.15(d,J=10.5Hz,1H,CH2CH=CH2),4.90(d,J=11.4Hz,1H,PhCH2),4.81(d,J=12.0Hz,1H,PhCH2),4.78(d,J=12.0Hz,1H,PhCH2),4.71(d,J=11.8Hz,1H,PhCH2),4.70(d,J=11.6Hz,1H,PhCH2),4.55–4.49(m,2H,PhCH2,1”-H),4.43(dd,J=11.7,6.1Hz,1H,1”-H),4.32(d,J=11.8Hz,1H,PhCH2),4.25(d,J=11.8Hz,1H,PhCH2),4.22–4.17(m,1H,2”-H),4.14(t,J=6.8Hz,1H,5-H),4.06(dd,J=9.5,3.6Hz,1H,2-H),4.02–3.90(m,4H,CH2CH=CH2 X 2,3-H,4-H),3.69–3.59(m,2H,3”-H X 2),3.50(t,J=8.3Hz,1H,6-H),3.40(dd,J=9.0,5.8Hz,1H,6’-H).13C NMR(100MHz,CDCl3)δ=166.16,138.73,138.58,138.57,137.90,134.34,132.83,129.92,129.52,128.25,128.17,128.14,128.03,127.99,127.70,127.49,127.41,127.34,127.27,116.97,97.12,78.69,76.15,74.85,74.67,74.03,73.19,72.89,72.84,72.22,69.55,69.35,68.51,64.96.HRMS(ESI)Calcd for C47H54NO9[M+NH4]+:776.3793,found:776.3804.。
[0066] Compound 8 was dissolved in a mixed solution of DCM and MeOH (10 / 1, 100 mL), followed by the addition of PdCl2 (500 mg, 2.8 mmol), stirred at room temperature for 8 hours until the reaction was complete, filtered through diatomaceous earth to remove the precipitate, and the filtrate was washed with saturated NaHCO3 and saturated brine in turn, dried over anhydrous NaSO4, filtered and concentrated. Purification by silica gel column chromatography gave a colorless oil 9 (9.8 g, 97%). 11H NMR (400 MHz, CDCl3) δ 8.05–8.01 (m, 2H, ArH), 7.57–7.50 (m, 1H, ArH), 7.45–7.15 (m, 21H, ArH), 5.01 (d, J = 3.7 Hz, 1H, 1-H), 4.90 (d, J = 11.2, 1H, PhCH2), 4.89 (d, J = 11.2 Hz, 1H, PhCH2), 4.75 (s, 2H, PhCH2 X 2), 4.71 (d, J = 11.5 Hz, 1H, PhCH2), 4.53 (d, J = 11.3 Hz, 1H, PhCH2), 4.41 (dd, J = 11.7, 6.2 Hz, 1H, 1”-H), 4.36–4.32 (m, 1H, CH2-glycerol), 4.30 (d, J = 12.0 Hz, 1H, PhCH2), 4.23 (d, J = 11.7 Hz, 1H, PhCH2), 4.14–4.06 (m, 2H, 2-H, 5-H), 4.05–3.97 (m, 3H, 3-H, 4-H, 2”-H), 3.77–3.70 (m, 1H, 6-H), 3.66 (dd, J = 11.8, 7.4 Hz, 1H, 6’-H), 3.49 (t, J = 8.4 Hz, 1H, 3”-H), 3.31 (dd, J = 8.9, 5.5 Hz, 1H, 3”-H). 13C NMR (100 MHz, CDCl3) δ = 166.22, 138.55, 138.41, 137.82, 137.68, 133.05, 129.80, 129.66, 128.48, 128.37, 128.36, 128.29, 128.17, 128.03, 128.01, 127.69, 127.62, 127.54, 127.52, 127.35, 99.74, 79.45, 79.38, 76.15, 74.80, 74.50, 74.44, 73.30, 72.50, 69.75, 68.31, 64.48, 62.29. HRMS (ESI) Calcd for C44H50NO9 [M+NH4]+: 736.3480, found: 736.3490. HRMS Calcd for C44H46KO9 [M+K]+: 757.2773, found: 757.2770.
[0067] Add to the reaction flask Molecular sieves, vacuum-baked the flask, cooled to room temperature and then purged with argon, added glycosyl donor 10 (17.8 g, 21.4 mmol), dry DCM (270 mL) and DMF (24.8 mL, 321.0 mmol), and stirred at room temperature for 20 minutes. The reaction mixture was then cooled to -78 °C, TfOH (1.9 mL, 21.9 mmol) was added to the reaction, and then TLC analysis showed that the glycosyl donor had completely disappeared and a new spot was generated. TBAI (39.5 g, 107.0 mmol) was then added, and TLC analysis showed that the second step of activation was completed. The reaction system was placed in an ice-water bath, and glycosyl acceptor 11 (12.3 g, 17.1 mmol) was added. The temperature was gradually raised to room temperature, and the reaction was allowed to proceed at room temperature for 48 hours. After TLC analysis showed that the reaction was completed, triethylamine was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with NaHCO3 (aq.), Na2S2O3 (aq.) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give a colorless oil 11 (20.7 g, 87%, α / β = 11.5 / 1). Forαisomer: 1H NMR (500 MHz, CDCl3) δ = 7.97–7.91 (m, 2H, ArH), 7.55–7.48 (m, 4H, ArH), 7.42–7.3 (m, 1H, ArH), 7.32–7.06 (m, 40H, ArH), 5.11 (d, J = 3.6 Hz, 1H, 1a-H), 4.84 (d, J = 11.0 Hz, 1H, PhCH2) ,4.82(d,J=11.0Hz,1H,PhCH2),4.71(d,J=3.6Hz,1H,1b-H),4.70(d,J=12.0Hz,1H,PhCH 2),4.68(d,J=11.5Hz,1H,PhCH2),4.65(d,J=12.0Hz,1H,PhCH2),4.60–4.56(m,3H,PhCH2 X 3),4.52(d,J=12.0Hz,1H,PhCH2),4.50(d,J=12.0Hz,1H,PhCH2),4.46(d,J=11.5Hz ,1H,PhCH2),4.43(d,J=11.5Hz,1H,PhCH2),4.44–4.41(m,1H,1”-H),4.32(dd,J=11. 7,6.4Hz,1H,1”-H),4.25(d,J=11.8Hz,1H,PhCH2),4.18(d,J=11.9Hz,1H,PhCH2),4. 16–4.11(m,1H,2”-H),4.09–4.06(m,1H,5a-H),3.94(dd,J=9.5,3.5Hz,1H,2a-H),3.91(dd,J=10.0,3.5Hz,1H,2b-H),3.88–3.83(m,3H,3a-H,4a-H,4b-H)3.81(dd,J=10.1,2.8Hz,1H,3b-H),3.70–3.66(m,1H,5b-H),3 .66–3.61(m,3H,6b,6b'-H,3”-H),3.50–3.43(m,2H,3”-H,6a’-H),3.34(dd,J=8.9,5.6Hz,1H,6a’-H)0.95(s,9H,tert-Butyl).13C NMR (125MHz, CDCl3)δ=166.26,138.89,138.87,138.78,138.73,138.66,138.10,135.52,133.38,133.26,132.85,13 0.14,129.74,129.69,129.66,128.35,128.30,128.26,128.23,128.11,128.07,127.98,127.72,127.68,127.64,127 .52,127.48,127.45,127.41,127.39,127.36,127.32,98.33,96.88,79.10,78.81,76.49,76.39,75.23,75.12,74.83 ,74.78,73.58,73.35,73.13,73.09,72.89,71.28,69.55,68.64,67.23,65.26,62.73,26.92,19.15.HRMS(ESI)Calcd for C87H96NO14Si[M+NH4]+:1406.6595,found:1406.6597.
[0068] Preparation of TBAF / AcOH mixture: Add acetic acid dropwise to a THF solution of TBAF (5 mL, 1 M in THF) until the pH of the mixture is 6. Dissolve compound 11 (1.1 g, 0.79 mmol, in 2 mL of THF) in THF (2 mL) and add the above TBAF / AcOH mixture, and stir at room temperature for 3 hours until the reaction is complete. Add saturated NH4Cl to quench the reaction and dilute with 50 mL of DCM. Filter the precipitate through a celite pad. Wash the organic layer with NH4Cl (aq) and brine, dry over Na2SO4, filter and concentrate. The residue is purified by silica gel column chromatography to give a semi-solid 12 (730 mg, 80%). 1H NMR(500MHz,CDCl3)δ=7.99–7.90(m,2H,ArH),7.47–7.39(m,1H,ArH),7.33–7.07(m,38H,ArH),5.06(d,J=3.7Hz,1H,1a-H),4.84(d,J=12.0Hz,1H,PhCH2),4.82(d,J=12.0Hz,1H,PhCH2),4.75(d,J=3.5Hz,1H,1b-H),4.73(d,J=11.5Hz,1H,PhCH2),4.71(d,J=12.0Hz,1H,PhCH2),4.68(d,J=12.4Hz,1H,PhCH2),4.67(d,J=12.4Hz,1H,PhCH2),4.62(d,J=11.5Hz,1H,PhCH2),4.59(d,J=11.5Hz,1H,PhCH2),4.56(d,J=12.0Hz,1H,PhCH2),4.54(d,J=11.5Hz,1H,PhCH2),4.50(d,J=11.5Hz,1H),4.46–4.42(m,3H,PhCH2,3”-H X 2),4.26(d,J=11.9Hz,1H,PhCH2,),4.19(d,J=11.8Hz,1H,PhCH2,),4.16–4.08(m,1H,2”-H),4.04(t,J=6.7Hz,1H,5a-H),3.96(dd,J=10.0,4.0Hz,1H,2a-H),3.95(dd,J=10.5,3.5Hz,1H,2b-H),3.88–3.82(m,2H,4a-H,3a-H),3.80(dd,J=10.1,2.9Hz,1H,3b-H),3.76(dd,J=10.6,6.3Hz,1H,3”-H),3.70(d,J=2.8Hz,1H,4b-H),3.64(t,J=5.8Hz,1H,5b-H),3.55(dd,J=10.5,6.0Hz,1H,3”-H),3.57–3.49(m,1H,6b-H),3.42(t,J=8.5Hz,1H,6a-H),3.34(dd,J=9.4,5.8Hz,1H,6a’-H),3.37–3.29(m,1H,6b’-H),1.85(bs,1H,OH).13C NMR(125MHz,CDCl3)δ=66.38,138.80,138.75,138.68,138.32,138.04,133.03,130.07,129.68,128.45,128.40,128.35,128.31,128.19,128.15,127.85,127.79,127.72,127.69,127.63,127.60,127.58,127.55,127.51,127.47,127.44,98.43,97.39,78.96,78.86,76.62, 76.40,75.32,75.09,74.85,74.58,74.11,73.41,73.39,73.18,73.05,71.05,69.70,68.75,67.25,64.74,62.37.HRMS(ESI)Calcd for C71H78NO14[M+NH4]+:1168.5417,found:1168.5430.
[0069] Add to the reaction flask Molecular sieves, vacuum-baked the bottle, cooled to room temperature and then purged with argon, added glycosyl donor 7 (6.0 g, 8.8 mmol), dry DCM (270 mL) and DMF (10.2 mL, 132.0 mmol), and stirred at room temperature for 20 minutes. The reaction mixture was then cooled to -78 °C, TfOH (0.7 mL, 8.8 mmol) was added to the reaction, and then TLC analysis showed that the glycosyl donor had completely disappeared and a new spot was generated. TBAI (16.2 g, 43.9 mmol) was then added, and TLC analysis showed that the second step of activation was completed. The reaction system was placed in an ice-water bath, and glycosyl acceptor 12 (8.1 g, 7.0 mmol) was added. The temperature was gradually raised to room temperature and reacted at room temperature for 48 hours. TLC analysis showed that after the reaction was completed, triethylamine was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with NaHCO3 (aq.), Na2S2O3 (aq.) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give colorless oil 13 (10.3 g, 89%, α / β = 16.8 / 1).
[0070] Compound 13 was dissolved in a DCM / MeOH (1 / 1) mixture, and NaOMe (1 M in MeOH) was added to adjust the pH to 9. The mixture was stirred at room temperature for 3 hours until the reaction was complete, and H + The pH of the resin was adjusted to 7. The resin was filtered off, the filtrate was concentrated, and the residue was purified by silica gel column chromatography to obtain a colorless oil 1 (4.6 g, 87%). 1H NMR(600MHz,CDCl3)δ7.28–7.08(m,56H,ArH),5.02(d,J=3.7Hz,1H,1a-H),4.813(d,J=11.4,1H,PhCH2),4.808(d,J=11.4,1H,PhCH2),4.77(d,J=11.4Hz,1H,PhCH2),4.72(d,J=11.4Hz,1H,PhCH2),4.708(d,J=3.6Hz,2H,1b-H,1c-H),4.709(d,J=11.4Hz,1H,PhCH2),4.70(d,J=11.4Hz,1H,PhCH2),4.652(d,J=11.4Hz,1H,PhCH2),4.650(d,J=12.0Hz,1H,PhCH2),4.62(d,J=11.6Hz,1H,PhCH2),4.58(d,J=12.0Hz,1H,PhCH2),4.57–4.50(m,5H,PhCH2 X 5),4.46–4.40(m,3H,PhCH2 X3),4.39(d,J=11.6Hz,1H,PhCH2),4.37(d,J=12.0Hz,1H,PhCH2),4.28(d,J=11.8Hz,2H,PhCH2 X2),4.00(t,J=6.3Hz,1H,5a-H),3.96–3.89(m,4H,2a-H,2b-H,2c-H,3b-H),3.89–3.83(m,3H,2”-H,3a-H,3c-H),3.82–3.76(m,3H,5b-H,5c-H,3b-H),3.73(d,J=2.8Hz,1H,4c-H),3.73–3.68(m,3H,4a-H,6b-H,6c-H),3.65(dd,J=9.7,6.2Hz,1H,3”-H),3.55(dd,J=12.2,5.0Hz,1H,6b’-H),3.49(dd,J=10.2,5.4Hz,1H,6c’-H),3.47(dd,J=9.6,7.2Hz,1H,1”-H),3.44–3.40(m,2H,6a-H,1”-H),3.32(dd,J=9.7,6.6Hz,1H,3”-H),3.27(dd,J=9.4,5.4Hz,1H,6a’-H). 13C NMR (150MHz, CDCl3) δ = 138.74, 138.70, 138.65, 138.52, 138.49, 137.89, 137.65, 128.37, 128.34, 128.29, 128.26, 128.2 1,128.16,128.15,128.06,127.93,127.85,127.83,127.71,127.64,127.56,127.54,127.47,127.41,127.36,127.34,98 .26,98.10,97.24,79.27,78.94,78.86,78.08,76.46,76.29,76.22,75.03,74.96,74.82,74.74,74.59,74.58,73.58,73 .45,73.38,73.36,73.08,73.07,72.92,72.78,69.82,69.41,69.40,69.29,68.70,67.29,67.05,63.06.HRMS(ESI)Calcd for C 98 H 104 NaO 18 [M+Na] + :1592.7148,found 1592.7168.
[0071] 2. Preparation of Compound 3-1
[0072]
[0073] Add to the reaction flask Molecular sieves, vacuum-baked the flask, cooled to room temperature and then purged with argon, added glycosyl donor 15 (12.0 g, 16.6 mmol), dry DCM (200 mL) and DMF (19.3 mL, 249 mmol), and stirred at room temperature for 20 minutes. The reaction mixture was then cooled to -78 °C, TfOH (1.5 mL, 16.6 mmol) was added to the reaction, and then TLC analysis showed that the glycosyl donor had completely disappeared and a new spot was generated. TBAI (30.7 g, 83.0 mmol) was then added, and TLC analysis showed that the second step of activation was completed. The reaction system was placed in an ice-water bath, and glycosyl acceptor 14 (1.6 mL, 13.3 mmol) was added. The temperature was gradually raised to room temperature and reacted at room temperature for 48 hours. TLC analysis showed that after the reaction was completed, triethylamine was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with NaHCO3(aq), Na2S2O3(aq.) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give 16 as a colorless oil (7.6 g, 83%, / β>20 / 1).1H NMR(400MHz,CDCl3)δ=7.33–7.14(m,15H,ArH),6.83–6.73(m,2H,ArH),4.91(d,J=10.8Hz,1H,PhCH2),4.80(d,J=10.8Hz,1H,PhCH2),4.72(d,J=10.8Hz,1H,PhCH2),4.71(d,J=3.6Hz,1H,1-H),4.63(d,J=11.6Hz,1H,PhCH2),4.52(d,J=10.8Hz,1H,PhCH2),4.49(d,J=10.4Hz,1H,PhCH2),4.28(t,J=6.0Hz,1H,2”-H),4.25–4.14(m,2H,6-H,6’-H),4.00(dd,J=8.4,6.3Hz,1H,1”-H),3.88(t,J=9.2Hz,1H,3-H),3.81–3.74(m,1H,5-H),3.72(s,3H,OMe),3.66(dd,J=8.4,6.1Hz,1H,1”-H),3.53(dd,J=10.6,5.8Hz,1H,3”-H),3.47(dd,J=10.6,5.8Hz,1H,3”-H),3.44(dd,J=9.6,3.6Hz,1H,2-H),3.39(dd,J=10.0,8.8Hz,1H,4-H),2.64(q,J=6.4,5.9Hz,2H,CH2),2.49(t,J=6.6Hz,2H,CH2),2.08(s,3H,CH2),1.34(s,3H,CH3),1.29(s,3H,CH3).13C NMR(100MHz,CDCl3)δ=206.13,172.41,159.36,138.65,137.87,130.18,129.55,128.39,128.35,128.05,127.88,127.80,127.57,113.83,109.40,97.27,81.75,79.57,75.62,75.03,74.51,72.64,69.04,68.82,66.92,63.15,55.21,37.78,29.76,27.74,26.81,25.42.HRMS(ESI)Calcd for C39H52NO11[M+Na]+:710.3535,found:710.3531.。
[0074] Compound 16 (7.6 g, 10.9 mmol) was dissolved in 80% acetic acid aqueous solution (100 mL), reacted at 85°C until complete, concentrated the reaction solution and purified by column chromatography to obtain a colorless oil (6.0 g, 84%). The colorless oil (6.0 g, 9.1 mmol) was dissolved in pyridine (70 mL), and myristic acid chloride (6 mL, 22 mmol) and DMAP (337 mg, 2.8 mmol) were added. The mixture was stirred at room temperature for 12 hours. After TLC analysis showed that the reaction was completed, methanol was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with 1N HCl (aq), H2O, NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to obtain a colorless oil 17 (8.5 g, 86%). 1 H NMR (400MHz, CDCl3) δ=7.40–7.21(m,14H,ArH),6.88–6.82(m,2H,ArH),5.27–5.20(m,1H,2”-H),4.97(d,J=10.8Hz,1H,PhCH2),4.87(d,J=10.9Hz ,1H,PhCH2),4.80(d,J=10.8Hz,1H,PhCH2),4.671(d,J=11.6Hz,1H,PhCH2),4.670(d,J=3.6Hz,1H,1-H),4.57(d,J=10.8Hz,1H,PhCH2),4.55(d,J =11.6Hz,1H,PhCH2),4.41(dd,J=11.9,3.7Hz,1H,1”-H),4.29(dd,J=11.9,4.5Hz,1H,6-H),4.24–4.17(m,2H,6’-H,1”-H),3.94(t,J=9.3Hz,1H,3 -H),3.80(s,3H,OMe),3.82–3.78(m,1H,5-H),3.74(dd,J=10.8,5.4Hz,1 H,3”-H),3.57–3.42(m,3H,2-H,4-H,3”-H),2.71(q,J=6.4,5.9Hz,2H,CH2 Lev),2.55(t,J=6.6Hz,2H,CH2 Lev),2.29(td,J=7.4,2.2Hz,4H,CH2 myristoyl),2.16(s,3H,CH3 Lev),1.67–1.55(m,4H,CH2myristoyl),1.37–1.19(m,40H,CH2 myristoyl),0.88(t,J=6.7Hz,6H,CH3 myristoyl). 13CNMR(100MHz, CDCl3)δ=206.14,173.28,172.93,172.40,159.34,138.64,137.89,130.22,129.4 3,128.38,128.36,128.05,127.90,127.78,127.58,113.85,97.46,81.64,79.69,75.63,75.00,7 2.72,69.72,68.96,66.31,63.00,62.43,55.20,37.78,34.26,34.08,31.89,29.78,29.66,29.6 5,29.62,29.48,29.33,29.29,29.12,29.11,27.73,24.89,24.88,22.65,14.08.HRMS(ESI)Calcd for C 64 H 100 NO 13 [M+NH4] + :1090.7189,found:1090.7195.
[0075] Compound 17 was dissolved in a DCM / MeOH mixture (9 / 1, 100 mL), DDQ (3.6 g, 15.6 mmol) was added and stirred at room temperature for 5 hours. After TLC analysis showed that the reaction was completed, methanol was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with NaHCO3 (aq), and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give a light yellow syrup 18 (6.2 g, 82%). 1H NMR(400MHz,CDCl3)δ=7.33–7.28(m,2H,ArH),7.27–7.16(m,8H,ArH),5.22–5.11(m,1H,2”-H),4.89(d,J=11.1Hz,1H,PhCH2),4.79(d,J=10.9Hz,1H,PhCH2),4.744(d,J=10.8Hz,1H,PhCH2),4.735(d,J=3.6Hz,1H,1-H),4.50(d,J=10.9Hz,1H,PhCH2),4.33(dd,J=11.9,4.2Hz,1H,1”-H),4.21(d,J=3.5Hz,2H,6-H,6’-H),4.06(dd,J=11.9,5.9Hz,1H,1”-H),3.80–3.70(m,2H,5-H,3”-H),3.67(t,J=9.0Hz,1H,3-H),3.60(dd,J=9.3,3.8Hz,1H,2-H),3.57–3.47(m,1H,3”-H),3.38(t,J=9.3Hz,1H,4-H),2.62(td,J=6.3,3.9Hz,2H,CH2 Lev),2.48(t,J=6.5Hz,2H,CH2Lev),2.23(m,4H,CH2 myristoyl),2.06(s,3H,CH3 Lev),1.60–1.48(m,4H,CH2 myristoyl),1.19(d,J=9.4Hz,40H,CH2 myristoyl),0.80(t,J=6.7Hz,6H,CH3 myristoyl). 13 C NMR(100MHz,CDCl3)δ=205.87,173.11,172.84,172.20,138.41,137.75,128.24,128.22,127.90,127.78,127.65,127.50,98.89,82.99,76.87,75.21,74.83,72.87,69.70,69.20,66.38,62.84,61.93,37.63,34.13,33.93,31.75,29.56,29.52,29.49,29.33,29.18,29.12,28.97,27.65,24.77,24.73,22.52,13.94.HRMS(ESI)Calcd for C 56 H 92 NO 12 [M+NH4] +:970.6614,found:970.6606.
[0076] Add to the reaction flask Molecular sieves, vacuum-baked the flask, cooled to room temperature and then purged with argon, added glycosyl donor 19 (6.1 g, 8.1 mmol), dry DCM (100 mL) and DMF (9.5 mL, 121.5 mmol), and stirred at room temperature for 20 minutes. The reaction mixture was then cooled to -78 °C, TfOH (0.7 mL, 8.1 mmol) was added to the reaction, and TLC analysis showed that the glycosyl donor had completely disappeared and a new spot was generated. The reaction system was then placed in an ice-water bath, glycosyl acceptor 18 (6.2 g, 6.5 mmol) was added, the temperature was gradually raised to room temperature, and the reaction was carried out at room temperature for 24 hours. After TLC analysis showed that the reaction was completed, triethylamine was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to obtain a colorless oil 20 (8.4 g, 79%). 1H NMR(400MHz,CDCl3)δ=7.65(d,J=7.2Hz,2H,ArH),7.62(d,J=7.3Hz,2H,ArH),7.43–7.19(m,28H,ArH),7.14–7.05(m,3H,ArH),6.99(t,J=7.5Hz,2H,ArH),5.18–5.12(m,1H,2”-H),5.04(d,J=3.5Hz,1H,1b-H),4.99(d,J=3.4Hz,1H,1a-H),4.96(d,J=10.8Hz,1H,PhCH2),4.94(d,J=10.8Hz,1H,PhCH2),4.88(d,J=11.0Hz,1H,PhCH2),4.86–4.74(m,5H,PhCH2 X 5),4.60(d,J=11.0Hz,1H,PhCH2),4.51(d,J=11.0Hz,1H,PhCH2),4.32(dd,J=12.1,3.2Hz,1H,1”-H),4.25(d,J=3.3Hz,2H,6a-H,6a’-H),4.18(dd,J=12.1,6.2Hz,1H,1”-H),4.07(t,J=9.3Hz,1H,3b-H),3.98(t,J=9.2Hz,1H,3a-H),3.96–3.91(m,H,5b-H),3.85–3.66(m,6H,5a-H,2a-H,3”-H,6b-H,6b’-H,4b-H),3.63–3.54(m,2H,3”-H,2b-H),3.43(t,J=9.4Hz,1H,4a-H),2.73–2.66(m,2H,CH2 Lev),2.54(t,J=6.5Hz,2H,CH2 Lev),2.32–2.20(m,4H,CH2 myristoyl),2.14(s,3H,CH3 Lev),1.64–1.52(m,4H,CH2myristoyl),1.25(t,J=3.9Hz,40H,CH2 myristoyl),1.03(s,9H,tert-Butyl),0.88(t,J=6.7Hz,6H,CH3 myristoyl). 13C NMR (100MHz, CDCl3)δ=206.02,173.16,172.90,172.39,138.61,138.32,138.11,137.87,135.75,135.58,133.53,133.31,129.50,129.47,128 .38,128.35,128.30,128.22,128.14,128.07,128.05,127.93,127.76, 127.72,127.68,127.59,127.54,127.50,127.36,127.29,96.11,94.39, 82.06,80.50,79.71,77.66,77.50,75.89,75.70,75.14,74.99,74.83, 72.74,71.94,69.90,69.14,66.24,63.07,62.70,62.53,37.78,34.23,3 4.04,31.88,29.73,29.66,29.62,29.48,29.47,29.32,29.30,29.27,2 9.11,27.76,26.87,24.91,24.84,22.65,19.26,14.07.HRMS(ESI)Calcd forC 99 H 138 NO 17 Si[M+NH4] + :1641.9762,found:1641.9777.
[0077] Compound 20 (8.4 g, 5.2 mmol) was dissolved in DCM (50 mL), followed by the addition of hydrazine hydrate (250 μL, 5.2 mmol), acetic acid (444 μL, 7.7 mmol) and pyridine (222 μL), and stirred at room temperature for 5 hours. After TLC analysis showed that the reaction was complete, acetone was added to quench the reaction and diluted with 100 mL DCM. The organic layer was washed with NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to obtain a semi-solid (6.6 g, 84%). The semi-solid (7.0 g, 4.6 mmol) was dissolved in pyridine (20 mL), followed by the addition of myristic acid chloride (1.5 mL, 5.5 mmol), DMAP (167 mg, 1.4 mmol), and stirred at room temperature for 3 hours. After TLC analysis showed that the reaction was complete, methanol was added to quench the reaction and diluted with 100 mL DCM. The organic layer was washed with 1N HCl(aq), H2O, NaHCO3(aq) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give 21 (6.8 g, 86%) as a colorless syrup.1 H NMR(400MHz,CDCl3)δ=7.61–7.51(m,4H,ArH),7.35–7.10(m,28H,2ArH),7.06–6.97(m,3H,ArH),6.96–6.84(m,2H,ArH),5.10–5.03(m,1H,2”-H),4.97(d,J=3.4Hz,1H,1b-H),4.92(d,J=3.2Hz,1H,1a-H),4.89(d,J=10.8Hz,1H,PhCH2),4.87(d,J=10.8Hz,1H,PhCH2),4.80(d,J=11.0Hz,1H,PhCH2),4.77–4.65(m,5H,PhCH2 X 5),4.52(d,J=11.0Hz,1H,PhCH2),4.41(d,J=10.9Hz,1H,PhCH2),4.24(dd,J=12.3,3.2Hz,1H,1”-H),4.17(d,J=3.3Hz,2H,6a-H,6a’-H),4.09(dd,J=12.1,6.2Hz,1H,1”-H),3.99(t,J=9.3Hz,1H,3b-H),3.91(t,J=9.6Hz,1H,3a-H),3.88–3.84(m,2H,5b-H),3.79–3.57(m,6H,3”-H,2a-H,5a-H,4b-H,6b-H,6b’-H),3.56–3.45(m,2H,3”-H,2b-H),3.37(t,J=9.4Hz,1H,4a-H),2.24–2.13(m,6H,CH2 myristoyl),1.51(p,J=7.7,7.1Hz,6H,CH2myristoyl),1.18(d,J=4.8Hz,60H,CH2myristoyl),0.95(s,9H,tert-Butyl),0.81(t,J=6.7Hz,9H,CH3 myristoyl). 13C NMR (100MHz, CDCl3)δ=173.51,173.27,172.97,138.64,138.62,138.36,138.13,137.84,135.82,135.65,133.54,133.34,129.59,129.54,12 8.46,128.40,128.31,128.22,128.18,127.95,127.86,127.84,127.7 8,127.71,127.67,127.64,127.58,127.47,127.39,96.14,94.38,82.1 3,80.58,79.72,77.72,77.60,76.04,75.80,75.14,75.11,74.92,72. 82,71.99,69.90,69.21,66.23,62.77,62.72,62.56,34.29,34.13,34. 11,31.97,29.75,29.73,29.70,29.66,29.56,29.41,29.38,29.36,29. 34,29.22,29.20,26.93,24.98,24.92,22.73,19.33,14.17.HRMS(ESI) . Calcd for C 108 H 158 NO 16 Si[M+NH4] + :1754.1378, found 1754.1359.
[0078] Compound 21 (7.2 g, 4.1 mmol) was dissolved in THF (200 mL), followed by the addition of 70% hydrogen fluoride pyridine solution (41 mL). The mixture was stirred at room temperature for 12 hours. After TLC analysis showed that the reaction was complete, NaHCO3 (aq) was added to quench the reaction and diluted with 200 mL DCM. The organic layer was NH4Cl (aq), washed with brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give a colorless oil 3-1 (5.0 g, 80%). 1H NMR(400MHz,CDCl3)δ=7.39–7.22(m,22H,ArH),7.22–7.10(m,3H,ArH),5.18–5.11(m,1H,2”-H),4.97(d,J=10.8Hz,1H,PhCH2),4.95(d,J=3.2Hz,1H,1b-H),4.948(d,J=3.6Hz,1H,1a-H),4.935(d,J=10.4Hz,1H,PhCH2),4.87(d,J=11.2Hz,2H,PhCH2 X 2),4.85(d,J=11.2Hz,1H,PhCH2),4.83(d,J=11.2Hz,1H,PhCH2),4.77(d,J=11.9Hz,1H,PhCH2),4.72(d,J=11.9Hz,1H,PhCH2),4.61(d,J=11.2Hz,1H,PhCH2),4.55(d,J=10.8Hz,1H,PhCH2),4.33(dd,J=12.3,3.2Hz,1H,1”-H),4.30–4.25(m,2H,6a-H,6a’-H),4.19(dd,J=12.2,6.3Hz,1H,1”-H),4.06(t,J=9.3Hz,1H,3b-H),3.99(t,J=9.3Hz,1H,3a-H),3.94–3.80(m,2H,2H,5b-H,5a-H),3.79–3.68(m,2H,3”-H,2a-H),3.59–3.45(m,6H,3”-H,4a-H,2b-H,4b-H,6b-H,6b’-H),2.36–2.20(m,6H,CH2myristoyl),1.66–1.51(m,6H,CH2 myristoyl),1.35–1.16(m,60H,CH2 myristoyl),0.88(t,J=6.7Hz,9H,CH3 myristoyl). 13C NMR (100MHz, CDCl3)δ=173.40,173.20,172.88,138.59,138.38,138.06,137.97,137.68,128.43,128.37,12 8.30,128.28,128.06,127.87,127.81,127.79,127.64,127.61,127.52,96.32,95.48,81.83,80.41,79.32, 77.77,77.25,76.13,75.98,75.53,75.13,74.86,73.01,71.33,69.77,69.20,66.33,34.22,34.08,34.04,3 1.89,29.65,29.64,29.48,29.33,29.28,29.15,29.12,24.90,24.88,24.85,22.65,14.09.HRMS(ESI)Calcd for C 92 H 136 NaO 16 [M+Na] + :1519.9721,found1519.9792.
[0079] 3. Preparation of Compound 3-2
[0080]
[0081] Add to the reaction flask Molecular sieves, vacuum-baked the flask, cooled to room temperature and then purged with argon, added glycosyl donor 22 (10.0 g, 14.0 mmol), dry DCM (168 mL) and DMF (16.2 mL, 210 mmol), and stirred at room temperature for 20 minutes. The reaction mixture was then cooled to -78 °C, TfOH (1.2 mL, 14.0 mmol) was added to the reaction, and then TLC analysis showed that the glycosyl donor had completely disappeared and a new spot was generated. TBAI (25.8 g, 70.0 mmol) was then added, and TLC analysis showed that the second step of activation was completed. The reaction system was placed in an ice-water bath, and glycosyl acceptor 14 (1.4 mL, 11.2 mmol) was added. The temperature was gradually raised to room temperature and reacted at room temperature for 24 hours. TLC analysis showed that after the reaction was completed, triethylamine was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with NaHCO3(aq), Na2S2O3(aq.) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give 23 as a colorless oil (6.1 g, 80%, α / β>20 / 1).1H NMR(400MHz,CDCl3)δ=7.39–7.21(m,16H,ArH),7.18–7.11(m,2H,ArH),6.84(d,J=8.5Hz,2H,ArH),4.97(d,J=10.9Hz,1H,PhCH2),4.83(d,J=11.6Hz,1H,PhCH2),4.81(d,J=2.8Hz,1H,1-H),4.79(d,J=11.2Hz,1H,PhCH2),4.70(d,J=11.7Hz,1H,PhCH2),4.59(d,J=12.4Hz,1H,PhCH2),4.58(d,J=11.6Hz,1H,PhCH2),4.47(d,J=11.2Hz,1H,PhCH2),4.46(d,J=12.0Hz,1H,PhCH2),4.35(t,J=6.0Hz,1H,2”-H),4.05(dd,J=8.4,6.3Hz,1H,3”-H),3.94(t,J=9.3Hz,1H,3-H),3.83–3.68(m,3H,3”-H,5-H,6-H,),3.75(s,3H,OMe),3.68–3.50(m,5H,2-H,4-H,1”-H X 2,6-H),1.41(s,3H,CH3),1.35(s,3H,CH3).13C NMR(100MHz,CDCl3)δ=159.23,138.73,138.11,137.76,130.17,129.47,128.20,127.76,127.74,127.71,127.52,127.39,113.69,109.26,97.36,81.75,79.49,77.45,75.48,74.89,74.43,73.31,72.55,70.18,68.91,68.34,66.88,55.07,26.70,25.32.HRMS(ESI)Calcd for C41H48KO9[M+K]+:723.2930,found 723.2927;Calcd for C41H52NO9[M+NH4]+:702.3637,found:702.3642.。
[0082] Compound 23 (7.0 g, 10.2 mmol) was dissolved in 80% acetic acid aqueous solution (100 mL), reacted at 85°C until complete, concentrated the reaction solution and purified by column chromatography to obtain a colorless oil (5.5 g, 83%). The colorless oil (5.0 g, 8.5 mmol) was dissolved in pyridine (40 mL), and myristoyl chloride (5 mL, 18.6 mmol) and DMAP (283 mg, 2.3 mmol) were added. The mixture was stirred at room temperature for 12 hours. After TLC analysis showed that the reaction was complete, methanol was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with 1N HCl (aq), H2O, NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to obtain a colorless oil 24 (6.5 g, 81%). 1 H NMR (400MHz, CDCl3) δ=7.36–7.22(m,16H,ArH),7.16–7.10(m,2H,ArH),6.85(d,J=8 .1Hz,2H,ArH),5.28–5.21(m,1H,2”-H),4.95(d,J=10.8Hz,1H,PhCH2),4.82(d,J=1 1.2Hz,1H,PhCH2),4.78(d,J=10.8Hz,1H,PhCH2),4.70(d,J=3.6Hz,1H,1-H),4.68( d,J=11.2Hz,1H,PhCH2)4.59(d,J=12.4Hz,1H,PhCH2),4.55(d,J=11.6Hz,1H,PhCH2) ,4.47(d,J=10.8Hz,1H,PhCH2),4.45(d,J=12.4Hz,1H,PhCH2),4.40(dd,J=12.0,3. 5Hz,1H,1”-H),4.18(dd,J=12.0,6.0Hz,1H,1”-H),3.91(t,J=9.2Hz,1H,3-H),3.80 (s,3H,OMe),3.77–3.67(m,3H,3”-H,5-H,6a-H),3.67–3.59(m,2H,4-H,6b-H),3.59 –3.49(m,2H,2-H,3”-H),2.28(t,J=7.7Hz,4H,CH2myristoyl),1.70–1.51(m,4H,CH2 myristoyl), 1.25 (s, 40H, CH2 myristoyl), 0.88 (t, J = 6.6Hz, 6H, CH3 myristoyl). 13C NMR (100MHz, CDCl3)δ=172.97,172.64,159.17,138.68,138.10,137.70,130.17,129.26,128.12,1 28.07,127.68,127.62,127.61,127.44,127.38,127.28,113.64,97.57,81.60,79.61,77.32,75.4 0,74.79,73.27,72.56,70.36,69.63,68.24,66.16,62.26,54.92,34.07,33.88,31.73,29.51,29. 47,29.46,29.45,29.31,29.17,29.11,28.94,28.92,24.72,24.70,22.50,13.94.HRMS(ESI)Calcd for C 66 H 100 NO 11 [M+NH4] + :1082.7291,found 1082.7304.Calcd for C 66 H 96 KO 11 [M+K] + :1103.6584,found1103.6581
[0083] Compound 24 was dissolved in a DCM / MeOH mixture (9 / 1, 100 mL), DDQ (2.6 g, 11.2 mmol) was added and stirred at room temperature for 5 hours. After TLC analysis showed that the reaction was completed, methanol was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with NaHCO3 (aq), and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give a light yellow syrup 25 (4.9 g, 94%). 1H NMR(400MHz,CDCl3)δ=7.39–7.35(m,2H,ArH),7.35–7.25(m,12H,ArH),7.17–7.12(m,2H,ArH),5.29–5.21(m,1H,2”-H),4.94(d,J=11.1Hz,1H,PhCH2),4.87(d,J=3.2Hz,1H,1-H),4.82(d,J=11.2Hz,2H,PhCH2 X 2),4.61(d,J=12.1Hz,1H,PhCH2),4.49(d,J=11.6Hz,2H,PhCH2 X 2),4.38(dd,J=11.9,4.2Hz,1H,3”-H),4.11(dd,J=11.9,5.7Hz,1H,3”-H),3.84(dd,J=11.0,4.5Hz,1H,1”-H),3.77–3.70(m,4H,2-H,3-H,5-H,6-H),3.68–3.59(m,3H,3”-H,4-H,6’-H),2.36–2.24(m,4H,CH2myristoyl),1.66–1.54(m,4H,CH2 myristoyl),1.37–1.23(m,40H,CH2 myristoyl),0.88(t,J=6.6Hz,6H,CH3 myristoyl). 13 C NMR(100MHz,CDCl3)δ=173.34,173.08,138.61,138.13,137.83,128.36,128.33,127.92,127.82,127.69,127.67,127.63,99.21,83.23,77.14,75.38,74.98,73.52,72.97,70.92,69.83,68.36,66.57,34.27,34.08,31.90,29.67,29.64,29.62,29.48,29.47,29.34,29.27,29.11,24.89,24.87,22.67,14.10.HRMS(ESI)Calcd for C 58 H 92 NO 10 [M+NH4] + :962.6716,found:962.6706.Calcd for C 58 H 88 NaO 10 [M+Na] + :967.6270,found:967.6212.
[0084] Add to the reaction flask Molecular sieves, vacuum-baked the flask, cooled to room temperature and then purged with argon, added glycosyl donor 19 (4.0 g, 4.8 mmol), dry DCM (60 mL) and DMF (5.6 mL, 72.0 mmol), and stirred at room temperature for 20 minutes. The reaction mixture was then cooled to -78 °C, TfOH (0.4 mL, 4.8 mmol) was added to the reaction, and TLC analysis showed that the glycosyl donor had completely disappeared and a new spot was generated. The reaction system was then placed in an ice-water bath, glycosyl acceptor 25 (3.6 g, 3.8 mmol) was added, the temperature was gradually raised to room temperature, and the reaction was carried out at room temperature for 24 hours. After TLC analysis showed that the reaction was completed, triethylamine was added to quench the reaction and diluted with 200 mL DCM. The precipitate was filtered out through a celite pad. The organic layer was washed with NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to obtain a colorless oil 26 (5.0 g, 80%). 1H NMR(400MHz,CDCl3)δ=7.68–7.60(m,4H,ArH),7.43–7.20(m,32H,ArH),7.13–7.03(m,5H,ArH),6.99–6.92(m,2H,ArH),5.19–5.12(m,1H,2”-H),5.03(d,J=4.0Hz,1H,1b-H),5.02(d,J=2.8Hz,1H,1a-H),4.95(d,J=10.8Hz,1H,PhCH2),4.92(d,J=11.8Hz,1H,PhCH2),4.89(d,J=10.4Hz,1H,PhCH2),4.85–4.71(m,5H,PhCH2 X 5),4.61(d,J=12.0Hz,1H,PhCH2),4.59(d,J=10.8Hz,1H,PhCH2),4.47(d,J=13.2Hz,1H,PhCH2),4.43(d,J=10.0Hz,1H,PhCH2),4.32(dd,J=12.1,3.3Hz,1H,1”-H),4.16(dd,J=12.1,6.1Hz,1H,1”-H),4.08(t,J=9.2Hz,1H,3b-H),4.02–3.91(m,2H,5b-H,3a-H),3.85–3.55(m,11H,3”-H X 2,2b-H,4b-H,6b-H,6b’-H,2a-H,4a-H,5a-H,6a-H,6a’-H),2.30–2.20(m,4H,CH2 myristoyl),1.61–1.51(m,4H,CH2 myristoyl),1.30–1.22(m,40H,CH2 myristoyl),1.02(s,9H,tert-Butyl),0.88(t,J=6.5Hz,6H,CH3 myristoyl). 13C NMR (100MHz, CDCl3)δ=173.21,172.93,138.67,138.63,138.37,138.24,138.21,137.88,135.76,135.61,133.55,133.29,129.48,1 29.45,128.38,128.32,128.26,128.18,128.14,128.11,128.05,127.81,127.71,127.67,127.62,127.58,127.56,127.55,127.51,1 27.28,96.37,94.45,82.11,80.52,79.74,77.70,77.61,75.87,75.73,75.22,74.96,74.83,73.45,72.74,71.80,70.74,69.96,68.4 4,34.24,34.05,31.90,29.68,29.66,29.64,29.49,29.34,29.31,29.30,29.13,26.86,24.90,24.85,22.67,14.10.HRMS(ESI)Calcd for C 101 H 138 NO 15 Si[M+NH4] + :1633.9864,found:1633.9859.
[0085] Compound 26 (4.3 g, 2.7 mmol) was dissolved in THF (100 mL), followed by the addition of 70% hydrogen fluoride pyridine solution (26 mL). The mixture was stirred at room temperature for 12 hours. After TLC analysis showed that the reaction was complete, NaHCO3 (aq) was added to quench the reaction and diluted with 200 mL DCM. The organic layer was washed with NH4Cl (aq), brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to give a colorless oil 3-2 (3.2 g, 87%). 1H NMR(600MHz,CDCl3)δ=7.31–7.13(m,26H,ArH),7.13–7.08(m,1H,ArH),7.07–7.00(m,4H,ArH),5.11–5.05(m,1H,2”-H),4.90(d,J=3.8Hz,1H,1a-H),4.89(4.87 4.90(d,J=11.4Hz,1H,PhCH2),(d,J=3.6Hz,1H,1b-H),4.83(d,J=10.7Hz,1H,PhCH2),4.79(d,J=11.2Hz,1H,PhCH2),4.76(d,J=11.4Hz,2H,PhCH2 X 2),4.74(d,J=10.8Hz,1H,PhCH2),4.68(d,J=11.9Hz,1H,PhCH2),4.64(d,J=11.9Hz,1H,PhCH2),4.53(d,J=11.6Hz,1H,PhCH2),4.52(d,J=12.0Hz,1H,PhCH2),4.41(d,J=11.6Hz,1H,PhCH2),4.40(d,J=12.0Hz,1H,PhCH2),4.25(dd,J=12.1,3.2Hz,1H,1”-H),4.10(dd,J=12.1,6.3Hz,1H,1”-H),3.98(t,J=9.3Hz,1H,3b-H),3.89(t,J=9.4Hz,1H,3a-H),3.81(dt,J=10.1,3.0Hz,1H,5a-H)3.71–3.62(m,4H,3”-H,6b-H,2b-H,5b-H),3.59(t,J=9.5Hz,1H,4b-H),3.56(dd,J=10.7,2.0Hz,1H,6b’-H),3.51–3.39(m,5H,4a-H,3”-H,6a-H,6a’-H,2a-H),2.19(t,J=7.6Hz,2H,CH2 myristoyl),2.15(t,J=7.6Hz,2H,CH2myristoyl),1.49(dt,J=13.0,7.2Hz,4H,CH2 myristoyl),1.27–1.07(m,40H,CH2myristoyl),0.80(t,J=7.0Hz,6H,CH3 myristoyl). 13C NMR (100MHz, CDCl3)δ=173.12,172.84,138.65,138.60,138.40,138.13,138.07,137.78,137.72,128.35,128.28,128.22,128.19,12 7.97,127.83,127.83,127.80,127.76,127.70,127.63,127.61,127.53,127.47,127.44,127.41,96.49,95.34,81.82,81.78,80.38, 79.33,77.84,77.82,77.79,77.19,76.06,75.83,75.44,74.93,74.76,73.42,72.88,71.17,70.70,69.84,68.20,66.35,62.53,61.2 3,34.17,33.98,31.90,31.82,29.60,29.56,29.41,29.26,29.23,29.20,29.04,24.84,24.77,24.76,22.59,14.04.HRMS(ESI)Calcd for C 85 H 120 NO 15 [M+NH4] +: 1394.8652,found:1394.8662.
[0086] 4. Preparation of Compound 5-1
[0087]
[0088] Add to the reaction flask Molecular sieves, vacuum bake the bottle, cool to room temperature and then pass argon, dissolve 1 (1.0 g, 0.64 mmol) and N, N-diisopropylammonium tetrazolium salt (218 mg, 1.27 mmol) in dry 6.4 mL DCM, stir at room temperature for 20 minutes, then add 2-cyanoethyl N, N, N, N-tetraisopropylphosphorodiamidite (303 μL, 0.96 mmol), continue stirring for 6 hours, TLC analysis shows that the precipitate is filtered out through a diatomaceous earth pad after the reaction is completed. The organic phase is washed with NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated to quantitatively obtain a semi-solid product 2-1, which is directly used in the next step of synthesis without purification. Add to the reaction bottle Molecular sieves, vacuum-baked the bottle, cooled to room temperature and then purged with argon, added freshly prepared 2 (1.1 g, 0.64 mmol) and 3-1 (666 mg, 0.444 mmol), dissolved in dry 6.4 mL DCM. Then tetrazole (89 mg, 1.27 mmol) was added and stirred at room temperature for 2 hours. TLC analysis showed that the starting material disappeared completely, the reaction system was placed in an ice-water bath, tert-butyl peroxide (120 μL) was added, and stirring was continued for 3 hours. TLC analysis showed that the molecular sieves were filtered out through a diatomaceous earth pad after the reaction was completed. The organic layer was washed with NaHCO3 (aq) and brine, dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column chromatography to obtain a pair of diastereomers 4-1 (1.07 g, 76%). 1 H NMR (600MHz, CDCl3, mixture of diastereoisomers) δ = 7.28–6.95 (m, 80H, ArH), 5.31 (s, 1H, anomeric H), 5.15 (d, J = 3.6Hz, 1H, anomeric H), 5.03–5.00 (m, 1H, 2-H Gro),4.89(d,J=3.7Hz,1H,anomeric H),4.88–4.85(m,1H),4.84–4.13(m,44H),4.11–4.08(m,2H),4.06–3. 70(m,25H),3.68–3.58(m,4H),3.54–3.31(m,11H),2.24–2.13(m,6H,3x CH2 myristoyl),2.12–2.04(m,1H,CH2cyanoethyl),1.86(t,J=6.0Hz,1H,3x CH2 cyanoethyl),1.55–1.44(m,6H,3x CH2myristoyl),1.31–1.02(m,60H,30x CH2 myristoyl),0.80(t,J=7.0Hz,9H,3xCH3myristoyl). 13 C NMR (150 MHz, CDCl 3,mixture of diastereoisomers)δ=173.42,173.16,172.81,138.90,138.86,138.84,138.78,138.65,138.20,138.14,138.03,128.43,128.41,128.39,128.37,128.35,128.32,128.30,128.27,128.24,128.22,128.15,128.13,128.02,127.90,127.85,127.83,127.79,127.77,127.73,127.70,127.66,127.46,127.42,127.40,127.35,127.30,127.26,116.66,98.79,98.66,98.43,98.30,96.20,96.01,95.76,95.43,95.33,81.64,80.31,79.58,79.50,79.44,79.16,79.01,78.95,78.21,78.13,76.28,76.07,75.89,75.49,75.25,75.10,74.98,74.79,74.64,73.77,73.46,73.43,73.36,73.32,73.06,72.98,72.95,72.90,72.77,72.63,69.81,69.68,69.54,69.32,69.02,68.82,67.11,66.45,62.04,61.85,34.26,34.08,31.91,29.69,29.66,29.64,29.51,29.33,29.30,29.20,29.16,24.95,24.90,24.88,22.66,14.07. 31 P NMR(202MHz,CDCl3,mixture of diastereoisomers)δ=-0.77,-0.91.HRMS(MALDI-TOF)Calcd forC 193 H 242 NNaO 36 P[M+Na] + :3205.6834,found:3205.682.
[0089] Compound 4-1 (170 mg, 0.05 mmol) was dissolved in DCM (20 mL), and a drop of DBU was added. The mixture was stirred at room temperature for 30 minutes until TLC analysis showed that the starting material completely disappeared. The product was purified by silica gel column chromatography and dissolved in a mixture of EtOAc / THF / EtOH / H2O (4 / 2 / 1 / 1, 8 mL). 10% palladium / carbon (30 mg) was added and catalytic hydrogenation was performed for 3 days until TLC analysis showed that the starting material completely disappeared. The precipitate was filtered off with diatomaceous earth and filter paper, concentrated, and a mixture of CHCl3 / MeOH / H2O (65 / 50 / 7, 20 mL) was added. The precipitate was collected to obtain the product 5-1 (39.5 mg, 44%). 1 H NMR (600MHz, CDCl3 / CD3OD / D2O 20 / 9 / 2, v / v / v) δ=5.14(dq,J=9.1,3.8,3.3Hz,1H,2-HGro),5.05(d,J=3.8Hz,1H,anomeric H),4.90(d,J=3.5Hz,1H,anomeric H),4.86–4.79(m,3H,3x anomeric H),4.37–4.35(m,1H,CH2),4.30(d,J=11.6Hz,1H,CH2),4.18–4.08(m,2H,2x CH2),4.04–3.89(m,10H),3.87–3.76(m,5H),3.76–3.59(m,13H),3.57– 3.49(m,4H),3.40–3.37(m,2H),3.25–3.22(m,1H),2.28–2.21(m,6H,3x CH2 myristoyl), 1.54–1.50 (m, 6H, 3x CH2 myristoyl), 1.21–1.18 (m, 60H, 30x CH2 myristoyl), 0.79 (t, J = 6.9Hz, 9H, 3x CH3 myristoyl). 13C NMR (150MHz, CDCl3 / CD3OD / D2O20 / 9 / 2, v / v / v)δ=174.37,174.16,173.56,99.07,98.54,98.21,97.11, 96.01,76.31,75.56,73.13,71.75,71.06,70.82,70.54,70.05,69.87,69.80,69.74,69.63,69.49,69 .39,69.14,68.77,68.51,67.14,66.76,65.50,64.13,62.78,61.34,34.19,34.08,34.04,31.80,29.57,29.55,29.53,29.49,29.44,29.26,29.24,29.22,29.13,29.09,29.05,24.86,24.81,22.52,13.75. 31 P NMR(202MHz,CDCl3 / CD3OD / D2O 20 / 9 / 2,v / v / v)δ=0.55.HRMS(MALDI-TOF)Calcd for C 78 H 142 Na2O 36 P[M+2Na] + :1731.8808,found:1731.880.
[0090] 5. Preparation of Compound 5-2
[0091] Compound 5-2 was prepared by referring to the preparation method of compound 5-1. 11H NMR (600 MHz, CDCl3 / CD3OD / D2O 30 / 13 / 2, v / v / v) δ = 5.15 (dt, J = 8.5, 4.2 Hz, 1H, 2-H Gro), 5.07 (s, 1H, anomeric H), 4.96 (d, J = 3.4 Hz, 1H, anomeric H), 4.90–4.81 (m, 3H, 3x anomeric H), 4.40–4.35 (m, 1H, CH2), 4.14–4.13 (m, 1H, CH2), 4.01–3.82 (m, 14H), 3.79–3.49 (m, 19H), 3.46–3.34 (m, 4H), 2.26–2.20 (m, 4H, 2x CH2 myristoyl), 1.54–1.48 (m, 4H, 2x CH2 myristoyl), 1.25–1.15 (m, 40H, 20x CH2 myristoyl), 0.79 (t, J = 6.9 Hz, 6H, 2x CH3 myristoyl). 13 13C NMR (125 MHz, CDCl3 / CD3OD / D2O 30 / 13 / 2, v / v / v) δ = 174.32, 173.88, 98.97, 98.55, 98.05, 96.57, 96.25, 75.79, 75.65, 73.05, 72.14, 71.69, 71.66, 71.56, 71.06, 71.06, 70.99, 70.85, 70.85, 69.98, 69.73, 69.73, 69.62, 69.62, 69.47, 69.46, 69.13, 69.00, 68.56, 68.56, 68.35, 66.95, 66.71, 65.82, 64.53, 64.53, 62.91, 61.31, 60.44, 49.27, 34.21, 34.08, 31.81, 29.59, 29.54, 29.46, 29.28, 29.23, 29.09, 29.05, 24.88, 24.81, 22.53, 13.77. 31 31P NMR (202 MHz, CDCl3 / CD3OD / D2O 30 / 13 / 2, v / v / v) δ = 0.62. HRMS (MALDI-TOF) Calcd for C 64 H 116 Na2O 35 P [M + 2Na] + : 1521.6825, found: 1521.686.
[0092] Preparation of Compound 5-3
[0093] Compound 5-3 was prepared by referring to the preparation method of compound 5-1. 1 H NMR (600MHz, CDCl3 / CD3OD / D2O20 / 9 / 2, v / v / v)δ=5.17–5.12(m,1H,2-H Gro),5.08(s,1H,anomeric H),4.91(d,J=3.5Hz,1H,anomeric H),4.86–4.85(m,2H,anomeric H),4.83(d,J=3.5Hz,1H,anomeric H),4.39–4.34(m,1H,CH2),4.33–4.30(m,1H,CH2),4.17(dd,J=12.2,6.5Hz,1H,CH2),4.11(dd,J=11.8,7.9Hz ,1H,CH2),4.08–3.78(m,13H),3.77–3.49(m,19H),3.39–3.33(m,2H),3.28–3.26(m,1H),2.27–2.24(m,6H,3x CH2 myristoyl),1.56–1.50(m,6H,3x CH2 myristoyl),1.26–1.16(m,60H,30x CH2 myristoyl),0.79(t,J=7.0Hz,9H,3x CH3 myristoyl). 13 CNMR(125MHz,CDCl3 / CD3OD / D2O 20 / 9 / 2,v / v / v)δ=174.08,173.87,173.25,98.38,97.79,97.23,96.73,95.64,75.91,74.08,7 2.75,71.42,70.84,70.53,70.18,69.70,69.60,69.51,69.34,69.27,69.17,69.00,68.66,68. 35,68.15,67.14,66.15,65.13,63.83,62.44,61.08,60.98,33.86,33.75,33.71,31.48,29.25,29.23,29.21,29.18,29.12,28.94,28.90,28.80,28.77,28.73,24.53,24.49,22.20,13.45. 31 P NMR(202MHz,CDCl3 / CD3OD / D2O 20 / 9 / 2,v / v / v)δ=0.96.HRMS(MALDI-TOF)Calcd for C 78 H 142Na2O 36 P[M+2Na] + :1731.8808,found:1731.873.
[0094] 7. Preparation of Compound 5-4
[0095] Compound 5-4 was prepared by referring to the preparation method of compound 5-1. 1 H NMR (600MHz, CDCl3 / CD3OD / D2O30 / 20 / 6, v / v / v)δ=5.15(qd,J=5.8,2.6Hz,1H,2-H Gro),5.07(d,J=2.9Hz,1H,anomericH),4.95(d,J=3.4Hz,1H,anomeric H),4.88(d,J=3.8Hz,1H,anomeric H),4.83–4.82(m,2H,anomeric H),4.36(dd,J=12.2,2.7Hz,1H,CH2),4.13–4.12(m,1H,CH2),4.09–3.89(m,8H),3.89–3.51(m,25 H),3.46–3.43(m,2H),3.42–3.34(m,2H),2.25–2.21(m,4H,2xCH2myristoyl),1.53–1.48(m,4H,2x CH2 myristoyl), 1.22–1.14 (m, 40H, 20x CH2 myristoyl), 0.79 (t, J = 6.9Hz, 6H, 2x CH3 myristoyl). 13 C NMR (150MHz, CDCl3 / CD3OD / D2O30 / 20 / 6, v / v / v)δ=173.90,173.48,98.35,97.76,97.21,96.21,95.9 0,75.50,72.78,71.78,71.39,71.29,70.82,70.74,70.47,69.66,69.58,69.49,69.34,69.25,69.15 ,68.93,68.65,68.32,68.13,67.11,66.16,65.44,62.49,61.06,60.94,60.26,33.81,33.67,31.40,29.16,29.14,29.12,29.04,29.02,28.85,28.81,28.66,28.62,24.47,24.40,22.11,13.32,13.31. 31P NMR(202MHz,CDCl3 / CD3OD / D2O 30 / 20 / 6,v / v / v)δ=0.62.HRMS(MALDI-TOF)Calcd for C 64 H 116 Na2O 35 P[M+2Na] + :1521.6825,found:1521.695.
[0096] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A compound, characterized in that It is selected from the compounds shown in the following formula I, Wherein, X is independently selected from: H or fatty acyl.
2. The compound according to claim 1, characterized in that The fatty acyl group may be a saturated fatty acyl group or an unsaturated fatty acyl group. Further, the fatty acyl group is -COC 13 H 27 .
3. The compound according to claim 1 or 2, characterized in that The compound also includes pharmaceutically acceptable salts or esters or solvates, tautomers, meso- and racemates, racemates, stereoisomers or metabolites thereof.
4. A method for preparing the compound according to any one of claims 1 to 3, characterized in that: The synthetic route of the compound shown in formula I includes:
5. The preparation method according to claim 4, characterized in that: The preparation method comprises: S1. Compound 1 and N,N-diisopropylammonium tetrazolium salt are reacted at room temperature for a period of time, and then 2-cyanoethyl N,N,N,N-tetraisopropylphosphorodiamidite is added to continue the reaction until completion, and the semi-solid product 2 is obtained by filtration and concentration, and is directly used in the next step of synthesis without purification; S2, reacting compound 2 and compound 3 under tetrazole conditions until the raw materials completely disappear, placing the reaction system in an ice-water bath, adding tert-butyl peroxide and continuing to stir until the reaction is complete, and purifying to obtain compound 4; S3. Removing the protecting group from compound 4 gives compound 5.
6. The preparation method according to claim 5, characterized in that: The compound 1 is compound 1-1 or compound 1-2; the compound 3 is compound 3-1 or compound 3-2; 7. The preparation method according to claim 5, characterized in that: The compound 4 is compound 4-1, compound 4-2, compound 4-3 or compound 4-4, and the compound 5 is compound 5-1, compound 5-2, compound 5-3 or compound 5-4; 8. The preparation method according to claim 6, characterized in that: The compound 1 is prepared by a glycosylation method based on a pre-activated O-glycosyl trichloroacetimidate donor; When the compound 1 is compound 1-1, its synthesis route is as follows: Specifically, the method comprises the following steps: (1) compound 6 and compound 7 are glycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 8; (2) the compound 8 is deprotected from allyl group to obtain compound 9-1, which is then glycosylated with compound 10 by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 11-1; (3) the compound 11-1 is deprotected from TBDPS protecting group to obtain compound 12-1, which is then glycosylated with compound 7 by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 13-1; (4) the compound 13-1 is deprotected from Bz protecting group to obtain compound 1-1; When the compound 1 is compound 1-2, its synthesis route is as follows: Specifically, the method comprises the following steps: (1) compound 6 and compound 7 are glycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 8; (2) compound 8 is deglycosylated by removing the Bz protecting group to obtain compound 9-2, which is then deglycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 11-2; (3) compound 11-2 is deglycosylated by removing the TBDPS protecting group to obtain compound 12-2, which is then deglycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 13-2; and (4) compound 13-2 is deglycosylated by removing the allyl group to obtain compound 1-2.
9. The preparation method according to claim 6, characterized in that: The compound 3 was prepared by a glycosylation method based on a pre-activated O-glycosyl trichloroacetimidate donor; When the compound 3 is compound 3-1, its synthesis route is as follows: Specifically, the method comprises the following steps: (1) Compound 14 and Compound 15 are glycosylated by a pre-activated O-glycosyl trichloroacetimidate donor method to prepare Compound 16; (2) Compound 16 is deprotected and myristoylated to obtain Compound 17, which is then glycosylated with Compound 19 by a pre-activated O-glycosyl trichloroacetimidate donor method to prepare Compound 20; (3) Compound 20 is deprotected by Lev and myristoylated to obtain Compound 21; (4) Compound 21 is deprotected by TBDPS to obtain Compound 3-1; When the compound 3 is compound 3-2, its synthesis route is as follows: Specifically, the method comprises the following steps: (1) compound 14 and compound 22 are glycosylated by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 23; (2) compound 23 is deprotected and myristoylated to obtain compound 24, which is then glycosylated with compound 19 by a method based on a preactivated O-glycosyl trichloroacetimidate donor to prepare compound 25; (3) compound 25 is deprotected by removing the TBDPS protecting group to obtain compound 3-2.
10. A composition, characterized in that The composition comprises the compound according to any one of claims 1 to 3.
Citation Information
Patent Citations
Phosphoryl mannopentaose and derivatives thereof, and preparation methods and application thereof
CN106608893A
Heteroaryl substituted aminopyridine compounds
CN109641906A
Cytotoxin molecule, conjugate and preparation method and application thereof
CN109912683A
Glycosylation reaction catalyst, glycosylation method and application
CN113926472A
Phosphoryl mannose pentasaccharide and derivatives thereof, and preparation method and use thereof
WO2017071152A1
